Stockscreener 앱 받기
42.40
0.47%
-0.20
시간 외 거래:
42.42
0.02
+0.05%
전일 마감가:
$42.60
열려 있는:
$42.53
하루 거래량:
13.65M
Relative Volume:
0.69
시가총액:
$61.45B
수익:
$20.62B
순이익/손실:
$3.56B
주가수익비율:
17.78
EPS:
2.3847
순현금흐름:
$3.48B
1주 성능:
-3.88%
1개월 성능:
-11.30%
6개월 성능:
-32.51%
1년 성능:
-56.43%
1일 변동 폭
$42.28
$43.30
1주일 범위
$41.94
$44.30
52주 변동 폭
$41.94
$105.65
보스턴사이언티픽 Stock (BSX) Company Profile
명칭
Boston Scientific Corp
전화
508-683-4000
주소
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, MDT, SYK, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
42.40 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
100.10 | 168.71B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
87.97 | 110.49B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
285.22 | 105.65B | 25.27B | 3.34B | 4.57B | 8.6334 |
EW
Edwards Lifesciences Corp
|
87.23 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
보스턴사이언티픽 Stock (BSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-30 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-10-03 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-09-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-16 | 개시 | Leerink Partners | Outperform |
| 2025-04-16 | 업그레이드 | Needham | Hold → Buy |
| 2025-01-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-10-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-06-30 | 개시 | CL King | Buy |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-12-22 | 개시 | Mizuho | Neutral |
| 2022-12-20 | 재개 | Citigroup | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-06 | 개시 | Wolfe Research | Outperform |
| 2022-05-27 | 업그레이드 | Needham | Hold → Buy |
| 2022-04-13 | 재개 | Truist | Buy |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-05-26 | 다운그레이드 | Needham | Buy → Hold |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2020-09-17 | 개시 | Truist | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Peer Perform |
| 2020-04-22 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Buy |
| 2019-12-30 | 재확인 | Cowen | Outperform |
| 2019-12-19 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2019-09-05 | 재개 | JP Morgan | Overweight |
| 2019-09-03 | 재개 | Barclays | Overweight |
| 2019-05-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-11-28 | 개시 | UBS | Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-10-02 | 재확인 | Morgan Stanley | Overweight |
| 2018-09-07 | 재확인 | Needham | Strong Buy |
| 2018-09-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-07-06 | 재확인 | Needham | Strong Buy |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-04-26 | 재확인 | Needham | Strong Buy |
모두보기
보스턴사이언티픽 주식(BSX)의 최신 뉴스
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 - marketscreener.com
Boston Scientific misses 2026 guidance as Boston Scientific stock faces a reset - AD HOC NEWS
Boston Scientific re-evaluates 2027 framework after cyberattack - scanx.trade
Boston Scientific stock after-hours: company warns cyber incident may affect 2026 results - AD HOC NEWS
Boston Scientific's MedSurg Diversification Bolsters Growth Prospects - Yahoo Finance
Boston Scientific stock ahead of the Xetra open as newsroom lists cybersecurity update - AD HOC NEWS
Boston Scientific (BSX) Secures $135.7M Cardiovascular Contract with U.S. Military - GuruFocus
Could Boston Scientific’s $300 Million Cyber Hit Be Mostly a 2026 Problem? - Yahoo Finance
FDA Flags Boston Scientific Catheter Recall - Benzinga
Boston Scientific (BSX) Faces A Recall, Is The 28% Undervaluation Still Compelling? - Yahoo Finance
FDA Finally Approves Watchman Device from Boston Scientific - Medical Product Outsourcing
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Boston Scientific stock gains 2.06 percent ahead of the open - AD HOC NEWS
Boston Scientific stock faces a weaker 2026 growth outlook - AD HOC NEWS
Wells Fargo cuts Boston Scientific stock price target on cyberattack impact - Investing.com
Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig - GlobeNewswire Inc.
Wells Fargo Adjusts Price Target on Boston Scientific to $48 From $50, Keeps Equalweight Rating - marketscreener.com
Boston Scientific stock slips before the bell after September 23 decline - AD HOC NEWS
Boston Scientific (BSX) Executive VP Arthur C. Butcher to Retire in January 2027 - gurufocus.com
Boston Scientific (NYSE: BSX) Announces Arthur C. Butcher's Retirement with $780,000 Base Salary as Senior Advisor - Kalkine Media
Boston Scientific Corporation Announces Retirement of Arthur C. Butcher from Executive Vice President and Group President, Medsurg and Asia Pacific, Effective January 1, 2027 - marketscreener.com
Form 8K Boston Scientific Corp For: 23 September By Investing.com - Investing.com Nigeria
Boston Scientific announces retirement of executive vice president Arthur C. Butcher - Investing.com
Form 8K Boston Scientific Corp For: 23 September - Investing.com India
Arthur C. Butcher to Retire as Executive VP & Group President at Boston Scientific - TradingView
Boston Scientific stock advances 2.1 percent ahead of the open - AD HOC NEWS
Boston Scientific (BSX) Stock Moves 2.74%: What You Should Know - finance.yahoo.com
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Boston Scientific stock holds near its yearly low after downgrade - ad-hoc-news.de
What Boston Scientific (BSX) Tells Us About the Healthcare Stocks Trade Right Now - Kalkine Media
Boston Scientific stock heads into the open after a 0.9% gain - ad-hoc-news.de
Boston Scientific stock holds steady as Oppenheimer cuts price target to USD 65 - ad-hoc-news.de
Oppenheimer Adjusts Price Target on Boston Scientific to $65 From $85, Maintains Outperform Rating - marketscreener.com
Boston Scientific stock holds steady as analysts weigh cyberattack impact - AD HOC NEWS
Citi downgrades Boston Scientific as cyberattack recovery compounds competitive pressure - MassDevice
Boston Scientific Shares Fall After Citigroup Downgrade - marketscreener.com
Boston Scientific (BSX) Stock Trades At A Discount On A 55% Slump - Yahoo Finance
Citi downgrades Boston Scientific on uncertain recovery path - Investing.com
Boston Scientific Can't Dislodge Rival's Heart Valve Patent - Law360
TD Cowen maintains Boston Scientific stock rating after cyberattack - Investing.com
Citigroup Downgrades Boston Scientific to Neutral From Buy, Adjusts PT to $50 From $57 - marketscreener.com
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Boston Scientific: A Great Company At A Deeply Discounted Price (Rating Upgrade) - Seeking Alpha
Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years - Benzinga
Boston Scientific Leans on Acquisitions to Drive Long-Term Growth - finance.yahoo.com
Boston Scientific Corp Share PriceBSX, RNS News, Articles, Quotes, & Charts (NYSE:BSX) - Proactive financial news
Boston Scientific (BSX) Didn’t Miss on Demand or Devices. A Cyberattack Just Broke Its Guidance. - Yahoo Finance
Why Did BSX Cut FY26 Guidance? CEO Details Three Unanticipated Factors At Bernstein Conference - Stocktwits
Boston Scientific stock falls as cyberattack clouds 2026 outlook - ad-hoc-news.de
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Boston Scientific fully restores operations after cyberattack - Yahoo Finance
보스턴사이언티픽 (BSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.44%
0.04%
자본화:
|
볼륨(24시간):